Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press33610.17650/1726-9776-2012-8-2-66-71DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряIMPACT OF SECONDARY TRANSURETHRAL RESECTION ON RECURRENCE RATES IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCERВЛИЯНИЕ ПОВТОРНОЙ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ НА ЧАСТОТУ РЕЦИДИВОВ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯKhalmurzaevO. A.ХалмурзаевО. А.Russian Federation
oybekkhalmurzaev@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва300620128266710608201406082014https://oncourology.abvpress.ru/oncur/article/view/336
The incidence of recurrences was analyzed in patients with non-muscle-invasive bladder cancer who had undergone primary or secondary transurethral resection (TUR). The 5-year incidence of recurrences was studied. The authors also discuss whether it is reasonable to use second-look (restaging) TUR, which allows this procedure to be recommended for routine clinical practice.
Проведен анализ частоты встречаемости рецидивов у пациентов с немышечно-инвазивным раком мочевого пузыря у пациентов с однократной и повторной трансуретральной резекцией (ТУР). Изучена частота встречаемости рецидивов в течение 5 лет. Также обсуждается целесообразность применения ТУР second look при рестадировании, позволяющая рекомендовать эту методику для рутинной клинической практики.
non-muscle-invasive bladder cancertransurethral resection of the bladdersecond lookincidence of recurrencesrestagingнемышечно-инвазивный рак мочевого пузырятрансуретральная резекция мочевого пузыряsecond lookчастота встречаемости рецидивоврестадирование1. Матвеев Б.П. Клиническая онкоурология. М., 2011.Матвеев Б.П. Клиническая онкоурология. М., 2011.2. Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466−77.Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466−77.3. Нerr H., Dalbagni G. Is «second −look» (re-staging) transurethral resection of bladder tumors a new standard of care? Arab J Urol 2011;9:7−10.Нerr H., Dalbagni G. Is «second −look» (re-staging) transurethral resection of bladder tumors a new standard of care? Arab J Urol 2011;9:7−10.4. Herr H.W. A restaging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97:1194−8.Herr H.W. A restaging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97:1194−8.5. Soloway M., Safer M., Vaidya A. Contemporary management of stage Tl transitional cell carcinoma of the bladder. J Urol (Baltimore) 2002;167:1573−83.Soloway M., Safer M., Vaidya A. Contemporary management of stage Tl transitional cell carcinoma of the bladder. J Urol (Baltimore) 2002;167:1573−83.6. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU guidelines on nonmuscle- invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303−14.Babjuk M., Oosterlinck W., Sylvester R. et al. EAU guidelines on nonmuscle- invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303−14.7. Schips L., Augustin H., Zigeuner R.E. et al. Is repeat transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220−3.Schips L., Augustin H., Zigeuner R.E. et al. Is repeat transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220−3.8. Grimm M.O. Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170 (2 Pt 1): 433−7.Grimm M.O. Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170 (2 Pt 1): 433−7.9. Brauers A., Buettner R., Jakse G. Second resection and prognosis in primary high risk superficial bladder cancer. J Urol 2001; 165:808−10.Brauers A., Buettner R., Jakse G. Second resection and prognosis in primary high risk superficial bladder cancer. J Urol 2001; 165:808−10.10. Herr H.W. A restaging transurethral resection of high risk superficial bladder cancer improves the initial response to BCG therapy. J Urol 2005;174:2134−7.Herr H.W. A restaging transurethral resection of high risk superficial bladder cancer improves the initial response to BCG therapy. J Urol 2005;174:2134−7.11. Dalbagni G. Bladder cancer: Restaging TUR reduces recurrence and progression risk. Nat Rev Urol 2010;7(12):649−50.Dalbagni G. Bladder cancer: Restaging TUR reduces recurrence and progression risk. Nat Rev Urol 2010;7(12):649−50.